Earnings call transcript: New China Life Insurance Q4 2025 reveals earnings miss, stock dips

New China Life Insurance reported FY2025 revenue of CNY 157.8B (+19% YoY) and net profit of CNY 36.3B (+38.3%), but its EPS of 1.1 USD missed the 1.96 USD forecast by 43.9%, sending the stock down 2.82% post-earnings. Management highlighted record premiums, a 34.7% ROE, a 5.94% dividend yield, and a continued shift toward participating insurance, with FY2026 EPS guidance of 1.57 USD. The call also emphasized higher equity allocation, asset-liability management, and AI-driven operating efficiencies amid a low-rate environment.

Analysis

The important signal here is not the headline earnings miss; it is that management is deliberately accepting near-term margin dilution to reprice the franchise toward participating and bancassurance distribution. That shift tends to compress new-business value in the next 2-4 quarters, but it improves capital efficiency and reduces duration mismatch risk over a 2-3 year horizon, which is the right tradeoff in a falling-rate regime. In other words, the market is likely discounting the accounting noise but underappreciating the duration of the strategic reset.

The second-order winner is not just the insurer itself but the ecosystem around products with higher savings/wealth-management content: banks, asset managers, and sales-force infrastructure providers that can monetize higher product complexity and longer retention. The potential loser is any peer still overdependent on traditional protection sales, because the market now has a cleaner template for how to defend value growth without relying on spread expansion. If this transition works, the industry’s competitive moat shifts from balance-sheet size to distribution quality, ALM sophistication, and data/AI-enabled customer servicing.

The contrarian point is that the stock may be less cheap than it looks. A low single-digit multiple can be a value trap if the next leg of growth comes from lower-margin mix and capital-market sensitivity; the apparent value only works if investment returns remain above liability costs and the dividend remains fully covered through a tougher rate cycle. The near-term catalyst is not earnings recovery but evidence in the next 1-2 reporting periods that participating mix is scaling without a sharper-than-expected drop in NBV or persistency.

Key Decisions for Investors

• Long CHL/2628 on a 3-6 month horizon if the market keeps extrapolating the EPS miss into a structural impairment story; risk/reward improves if the name holds dividend support and management continues to guide to stable premium growth.
• Pair trade: long insurers with explicit ALM/participating-product transition progress versus short a peer basket still dependent on traditional spread products; target a 10-15% relative move over 2 quarters if the rate environment stays soft.
• Buy dips in large Chinese banks with strong bancassurance franchises over weaker standalone life insurers; the channel winner should capture higher fee income and cross-sell leverage as product complexity rises.
• Avoid chasing the stock on the first post-earnings bounce; wait for confirmation that NBV and persistency remain stable in the next two months, since that is the key de-risking event for the valuation multiple.
• If available, use covered calls on the insurer for income capture: the dividend looks supportive, but upside is likely capped until the market sees proof that the lower-margin mix is not eroding ROE faster than investment income can offset.